Jove
Visualize
Contact Us

Related Experiment Videos

Malignant hyperthermia: clinical features and management.

Michael J Pritchard1

  • 1Whiston Hospital NHS Trust, Prescot, Merseyside.

Nursing Times
|July 4, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

'The little things count': delivering dignified care.

Nursing times·2018
Same journal

The heart of the hospital.

Nursing times·2018
Same journal

The nurse's role in caring for people with dementia.

Nursing times·2018
Same journal

Hepatitis C and the ongoing challenge of genotype 3.

Nursing times·2018
Same journal

Implementing change in older people's acute care.

Nursing times·2018
Same journal

A total health economy approach to revalidation.

Nursing times·2018
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Malignant hyperthermia (MH) is a rare, life-threatening reaction to anesthesia or certain drugs. Prompt diagnosis and treatment with dantrolene are crucial for survival.

Area of Science:

  • Medical Science
  • Anesthesiology
  • Pharmacology

Background:

  • Malignant hyperthermia (MH) is a critical pharmacogenetic disorder.
  • It presents as a hypermetabolic crisis, often triggered by volatile anesthetics or succinylcholine.
  • MH can also be triggered by recreational drugs like Ecstasy.

Purpose of the Study:

  • To highlight the critical importance of recognizing Malignant hyperthermia.
  • To inform practitioners about MH triggers and clinical signs.
  • To outline the essential treatment protocols for Malignant hyperthermia.

Main Methods:

  • Review of clinical manifestations and triggers of Malignant hyperthermia.
  • Analysis of diagnostic challenges and treatment strategies.
  • Emphasis on the role of anesthesiologists and critical care teams.

Related Experiment Videos

Main Results:

  • Malignant hyperthermia symptoms manifest only upon exposure to specific agents.
  • Delayed diagnosis of MH significantly increases mortality risk.
  • Successful management relies on immediate cessation of triggering agents and dantrolene administration.

Conclusions:

  • Awareness of Malignant hyperthermia triggers and symptoms is vital for healthcare providers.
  • Rapid diagnosis and intervention, including dantrolene and body cooling, are essential for patient survival.
  • Further research into genetic predispositions and improved diagnostic tools for MH is warranted.